NF

Virtus Dividend, Interest & Premium Strategy Fund

NFJFinancial ServicesNASDAQ

Asset Management

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$149.7M
+14.0% YoY
Net Income
$148.9M
+14.2% YoY

Scan Results

Daily timeframe
DateIndicatorDetails
Jun 29 MACD Negative CrossoverHistogram -0.0168, negative momentum
Jun 27 MACD Negative CrossoverHistogram -0.0056, negative momentum
About Virtus Dividend, Interest & Premium Strategy Fund

Part of the financial services sector, Virtus Dividend, Interest & Premium Strategy Fund (NFJ) is listed under Asset Management. With a market capitalization of $1.41B, it sits in small-cap territory. The fund is co-managed by Allianz Global Investors U.S.

Key stats
Market Cap$1.41B
P/E (TTM)9.44
EPS$1.59
Beta1.10
52W Change+16.8%
Dividend Yield8.10%
ROE10.8%
Analysis

Virtus Dividend, Interest & Premium Strategy Fund reports $33.5M in cash and $0 in total debt. ROE of 10.8% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 0.7% is on the lower side, which is common in asset-heavy industries. Revenue has grown from -$107.7M (2023) to $149.7M (2026), reflecting a 239% increase over the period.

Investors considering Virtus Dividend, Interest & Premium Strategy Fund should weigh the typical risks associated with NFJ's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing NFJ's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Financial Services stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms